Cargando…
Expanding the molecular spectrum of tenosynovial giant cell tumors
BACKGROUND: While great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge. The canonical oncogenic fusion CSF1::COL6A3 is not systematically observed, suggesting that other oncogenic...
Autores principales: | Gauduchon, Thibault, Vanacker, Helene, Pissaloux, Daniel, Cassier, Philippe, Dufresne, Armelle, Karanian, Marie, Meurgey, Alexandra, Bouhamama, Amine, Gouin, François, Ray-Coquard, Isabelle, Blay, Jean-Yves, Tirode, Franck, Brahmi, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691341/ https://www.ncbi.nlm.nih.gov/pubmed/36439507 http://dx.doi.org/10.3389/fonc.2022.1012527 |
Ejemplares similares
-
Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)
por: Brahmi, Mehdi, et al.
Publicado: (2020) -
Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History
por: Brahmi, Mehdi, et al.
Publicado: (2020) -
Very long‐term survivors among patients with metastatic soft tissue sarcoma
por: Carbonnaux, Mélodie, et al.
Publicado: (2019) -
Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023) -
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
por: Arnaud-Coffin, Patrick, et al.
Publicado: (2020)